Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Solid Tumors
2017-005076-26Phase 2Active
- Sponsor
- Seagen Inc.
- Start
- Sep 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tisotumab vedotin in colorectal cancer (CRC), pancreatic cancer (PC), Pulmonary squamous cell carcinoma and 1 more (4 arms), sponsored by Seagen Inc. Primary endpoints: Antitumor activity (Parts A, B, and C) and Safety (Parts A, B, and C). Started Sep 2018; status: active.
02
Drugs
tisotumab vedotin
03
Conditions
colorectal cancer (CRC)pancreatic cancer (PC)Pulmonary squamous cell carcinomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2017-005076-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005076-26.